icon-    folder.gif   Conference Reports for NATAP  
 
  Back grey_arrow_rt.gif
 
 
 
 
 
ISLATRAVIR (ISL, MK-8591) SAFETY ANALYSIS THROUGH WEEK 48 FROM A PHASE 2 TRIAL IN TREATMENT NAÏVE ADULTS WITH HIV-1 INFECTION
 
 
  Presented at the 23rdInternational AIDS Conference; San Francisco & Oakland, California, USA
https://go.aws/2Ak3eKp
 
Reported by Jules Levin
 
July 06-10, 2020
 
E. DeJesus1, J.-M. Molina2, Y. Yazdanpanah3, A. AfaniSaud4, C. Bettacchi5, C. Chahin Anania6, S.O. Klopfer7, A Grandhi7,
K. Eves7, M.N. Robertson7, P. Sklar7, C. Hwang7, G.J. Hanna7, T. Correll7 1Orlando Immunology Center, Orlando, United States, 2St-Louis Hospital and University, Department of Infectious Disease, Paris, France, 3Bichat Hospital, Paris, France, 4University of Chile, Santiago, Chile, 5North Texas Infectious Diseases Consultants, Dallas, Texas, 6Hospital HernánHenríquezAravenaof Temuco, Temuco, Chile, 7Merck & Co., Inc., Kenilworth, NJ, USA DeJesus IAC 2020

0707201

0707202

0707203

0707204

0707205